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Abstract
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects
tumor growth by targeting cellular metabolic proliferation pathways and delays
renal cell carcinoma (RCC) progression. Preclinical evidence suggests that base-
line elevated tumor glucose metabolism as quantified by FDG-PET ([18F] fluoro-
deoxy-glucose positron emission tomography) may predict antitumor activity.
Metastatic RCC (mRCC) patients refractory to vascular endothelial growth fac-
tor (VEGF) pathway inhibition were treated with standard dose everolimus.
FDG-PET scans were obtained at baseline and 2 weeks; serial computed tomogra-
phy (CT) scans were obtained at baseline and every 8 weeks. Maximum standard-
ized uptake value (SUVmax) of the most FDG avid lesion, average SUVmax of
all measured lesions and their corresponding 2-week relative changes were exam-
ined for association with 8-week change in tumor size. A total of 63 patients
were enrolled; 50 were evaluable for the primary endpoint of which 48 had both
PET scans. Patient characteristics included the following: 36 (72%) clear cell his-
tology and median age 59 (range: 37–80). Median pre- and 2-week treatment
average SUVmax were 6.6 (1–17.9) and 4.2 (1–13.9), respectively. Response eva-
luation criteria in solid tumors (RECIST)-based measurements demonstrated an
average change in tumor burden of 0.2% (32.7% to 35.9%) at 8 weeks. Relative
change in average SUVmax was the best predictor of change in tumor burden (all
evaluable P = 0.01; clear cell subtype P = 0.02), with modest correlation. Baseline
average SUVmax was correlated with overall survival and progression-free sur-
vival (PFS) (P = 0.023; 0.020), but not with change in tumor burden. Everolimus
therapy decreased SUVs on follow-up PET scans in mRCC patients, but changes
were only modestly correlated with changes in tumor size. Thus, clinical use of
FDG-PET-based biomarkers is challenged by high variability.
Introduction
The oral mTOR (mammalian target of rapamycin) inhibi-
tor, everolimus, affects tumor growth by targeting cellular
metabolic proliferation pathways and delays renal cell car-
cinoma (RCC) progression [1, 2]. Although everolimus is
considered a standard treatment for patients with pro-
gression after vascular endothelial growth factor receptor
(VEGFR) tyrosine kinase inhibition, identifying patients
who have a prolonged response to therapy is critical as
the typical response rate is less than 10% and most pro-
gress rapidly [1]. Therefore, predictive biomarkers are
needed to aid clinicians in determining which patients
may benefit from mTOR inhibition.
One feature of RCC cells and tumors that has recently
garnered significant attention is the altered metabolic
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properties of these tumors [3]. Dysregulated hypoxia sig-
naling [4] and activation of the phosphoinositide 3-kinase
pathway [5] make renal carcinoma a natural fit for bio-
marker studies that incorporate metabolic profiling. These
tumors commonly display transcriptional activation of
targets of the hypoxia-inducible factor (HIF) such as the
glucose transporter, GLUT1 [6], rate-limiting glycolytic
enzymes [7], and PDK1 [8] that blocks pyruvate entry
into the Kreb’s cycle. Everolimus, an oral mTOR com-
plex-1-targeted agent, is currently an approved single
agent for its efficacy to improve progression-free survival
(PFS) in patients who have previously been treated with a
VEGFR tyrosine kinase inhibitor [2]. To this end, murine
models suggest that pretherapy elevated tumor glucose
uptake as quantified by positron emission tomography
(PET) with [18F] fluorodeoxy-glucose (FDG-PET) may
predict antitumor activity to mTOR inhibition [9] or
those patients more likely to achieve a more durable per-
iod of disease control.
Moreover, several lines of recently published data have
demonstrated a correlation of sequential FDG-PET uptake
with the activity of VEGFR tyrosine kinase inhibitors, the
other major class of targeted agents used in this disease
[10]. In one study, time to progression in patients treated
with the VEGFR inhibitor, sunitinib [11], was inversely
correlated with FDG-PET uptake by the tumors. A second
study examined the relationship between FDG-PET
uptake and the response in primary tumors to treatment
with another VEGFR tyrosine kinase inhibitor, sorafenib,
similarly demonstrating that those tumors with the high-
est avidity for FDG-PET tracer signal were less likely to
respond to therapy [12]. These studies indicate that the
biology of these tumors is likely highly divergent between
those that produce a strong metabolic signal with FDG-
PET imaging, and those that have more limited glucose
uptake. While these relationships may simply reflect a
biological indicator of the aggressiveness of the disease, in
the setting of examining mTOR inhibitor therapy the
potential for altered metabolic programming to directly
influence the response to such agents is more mechanisti-
cally related.
On the basis of the preclinical data we primarily
hypothesized that baseline FDG-PET uptake would corre-
late with mTOR antitumor activity in renal cancer. We
thus conducted a phase II trial to begin to evaluate this
hypothesis in the context of oral everolimus therapy – on
the basis of the aforementioned clinical data we also
planned to explore the relationship between changes in
FDG-PET uptake and changes in tumor size and patient
outcome. In order to minimize trial size, we chose change
in tumor burden at 8 weeks as assessed by response eva-
luation criteria in solid tumors (RECIST) measurements
as the primary endpoint since recent analyses by our




This trial was designed as a single arm, nonblinded phase
II study conducted at four sites. Eligible patients were
adults with metastatic RCC of any histologic subtype
refractory to VEGFR tyrosine kinase inhibitors. Multiple
histologic subtypes were allowed because at the time of
study initiation, it was known that all histologies appar-
ently benefitted from mTOR inhibition. No prior mTOR
inhibitor therapy was allowed, but there were no other
restrictions on the number of prior therapies. Patients
were required to have a WHO performance status of ≤2,
baseline organ function including estimated creatinine
clearance of >10 mL/min (by Cockroft-Gault), adequate
bone marrow function defined by an absolute neutrophil
count ≥1.5 9 109/L, platelets ≥100 9 109/L, hemoglobin
>9 g/dL, adequate liver function defined by: serum bili-
rubin ≤1.5 9 upper limit of normal (ULN), and serum
transaminases activity ≤3 9 ULN (except serum tran-
saminases <5 9 ULN if the patient had liver metastases).
The trial also required no evidence of viral hepatitis, no
evidence of uncontrolled diabetes, and ability to tolerate
oral medications. Appropriate informed consent was
obtained from patients prior to study initiation.
Treatment plan
Patients received a fixed dose of everolimus (10 mg)
taken orally daily until progression or unacceptable toxic-
ity. Dose reductions to 5 mg daily and 5 mg every other
day were specified for grade 3 medication-related toxicity
based on National Institutes of Health-National Cancer
Institute Common Terminology Criteria for Adverse
Events, version 3.0. Grade 4 toxicities resulted in discon-
tinuation of treatment as did a dose delay of greater than
21 days or inability to tolerate 5 mg every other day.
Imaging
FDG-PET/computed tomography (CT) scans were
obtained at baseline (up to 2 weeks prior to start of ther-
apy) and at day 14 (1) from start of therapy. FDG was
obtained commercially and PET protocols were performed
with standardized equipment and protocol that account
for glucose levels as follows. Patients were fasting for at
least 4 h and have a serum glucose concentration of
<200 mg/dL. If the serum glucose was ≥200 mg/dL, delay-
ing the scan 1 day in order to allow medical correction
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was considered. Insulin was not be used immediately prior
to the scan to correct glucose unless medically necessary.
In brief, patients were injected with 0.14–0.21 mCi/kg
18F-FDG; the dose remaining in the tubing and syringe, as
well as any spilled dose, was recorded. Whole body imag-
ing (angle of the jaw to mid-thigh) began 90  10 min
after injection using a two- or three-dimensional acquisi-
tion mode (as appropriate for the equipment used at each
site) with attenuation correction. The PET viewing and
analysis software were analyzed using the commercially
available PET software MIM (MIM Software Inc., Cleve-
land, OH). The mean standardized uptake value (SUV) of
normal liver, not involved with cancer, was calculated and
recorded and used as an internal quality control metric.
This value was to verify that changes in measured tumor
SUV values were valid across a patient’s scans as there are
many sources of SUV variability. Serial CT scans were
obtained at baseline and every 8 weeks. The treating phy-
sician or investigator was blinded to the FDG-PET results.
A single, central reviewer (a nuclear radiologist) evalu-
ated FDG-PET results and was blinded to tumor size
evaluations. Maximum SUV (SUVmax) of the most FDG
avid lesion, the average SUVmax (avgSUVmax) of all
measured lesions, and the corresponding 2-week relative
change were examined for association with 8-week change
in tumor size. Of note, no a priori criteria for metabolic
response or nonresponse were specified and changes in
SUV metrics were analyzed as continuous variables.
Patients were reevaluated at their treating site for
tumor measurements and response every 8 weeks utilizing
multi-detector spiral CT techniques using a 5-mm contig-
uous reconstruction algorithm of at least the chest, abdo-
men, and pelvis. All measurable lesions up to a maximum
of five lesions per organ and 10 lesions in total, represen-
tative of all involved organs, should be identified as target
lesions and recorded and measured at baseline. Target
lesions were selected on the basis of their size (lesions
with the longest diameter) and their suitability for accu-
rate repeated measurements. RECIST [13] measurements
were derived from these standard tumor measurements.
Statistical considerations
The primary endpoint was to explore whether baseline
uptake on FDG-PET was associated with changes in
tumor burden. Tumor burden was chosen as a primary
endpoint as it correlates well with PFS in RCC [14] and
requires fewer patient resources [15]. Although responses
by RECIST criteria are the minority after everolimus ther-
apy, decreases in tumor size are commonly seen [16].
High- and low-uptake groups were defined based on av-
gSUVmax as avgSUVmax >4 and avgSUVmax ≤4 [17,
18], respectively. The primary endpoint was continuous
change in tumor size based on the RECIST criteria from
baseline to 8 weeks. Everolimus was expected to be less
active in patients with low uptake, and the change in
tumor size was expected to be a 20% average increase in
the low-uptake group, and a 10% average decrease in the
high-uptake group. Based on prior imaging experiences,
70% of patients were expected to have high FDG-PET
uptake [17, 18]. Tumor size changes were expected to be
approximately normally distributed when expressed on a
logarithmic scale [19, 20].
The 20% increase in the low FDG-PET uptake group
and the 10% decrease in tumor size in the low- and high-
uptake groups correspond to a difference of 0.29 on the
log scale. Our data from patients with metastatic renal
cell cancer treated with sorafenib [20] suggested that the
standard deviation of the mean percent change in tumor
size was 33%, which corresponds to SD = 0.40 on the log
scale. A total sample size of 60 patients (42 high uptake
and 18 low uptake) was planned to provide 81% power
to detect a difference of this magnitude with a two-sided
a = 0.10 based on a two-sample t-test. A planned second-
ary objective was to correlate the changes in FDG-PET
uptake at 2 weeks with changes in tumor size using Pear-
son correlation coefficient. A sample size of 60 patients
would provide 80% power to detect a true correlation of
0.31 or higher, based on a two-sided a = 0.1. Another
secondary objective was to determine these associations
specifically in patients potentially with von Hippel Lindau
pathway inactivation, which was done by separately exam-
ining the subset of patients with clear cell carcinoma.
The relationship between uptake parameters and tumor
size changes were further analyzed using linear regression.
Fisher’s exact test was used to test for independence of
two categorical variables. PFS and overall survival (OS)
were estimated using the method of Kaplan–Meier, and
differences between groups were assessed using the log-
rank test. Cox proportional hazards regression models
were used to examine the effect of uptake parameters as
continuous variables, and to estimate hazard ratios
(HRs). Average SUVmax across all lesions was used for




Participants were recruited from December 2007 to June
2010. Sixty-three patients signed consent. There were two
screen failures and one patient who never began the trial.
Thus, as proposed, 60 patients finished baseline screening
and started treatment. Fifty patients completed both CT
scan time points (enrollment, week 8) and a baseline
ª 2013 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 547
J. L. Chen et al. FDG-PET as a Predictive Biomarker in mRCC
FDG-PET scan (see Fig. 1) and 48 completed the second
FDG-PET scan for secondary endpoint analysis.
Patient characteristics
Median patient age was 60 (70%) with a male predomi-
nance. Of the 50 evaluable patients, the histologic break-
down was as follows: 36 clear cell (median baseline
avgSUVmax = 6.4; range 1.8–17.9), four papillary cell
(median avgSUVmax = 7.3; range 4.1–14.2), four chromo-
phobe (median avgSUVmax = 2.1; range 1–8.9), and six
unclassified tumors (median avgSUVmax = 10.9; range
6.3–13.7). The median number of target lesions at baseline
was three (range 1–9). The majority of patients had at
least two lines of prior therapy (with at least one VEGFR
tyrosine kinase inhibitor containing regimen) and had a
clear cell subtype (72%). There was a difference in the
proportion of patients with low uptake among renal cell
subtypes (P = 0.047) (Table 1). Although avgSUVmax was
highly variable, patients with chromophobe tumors were
more likely to have avgSUVmax ≤4 (75%), although there
were only four such patients.
Response to everolimus
All patients were treated at the planned dose. The major-
ity of patients (86%) had stable disease at the 8-week
time point. The range of responses overall and by tumor
subtype is shown in Table 2 and Figure 2A. For an aver-
age of 13.6 months (range 1–34.8 months), patients were
under follow-up.
The primary analysis explored the association of the
log-transformed change in tumor size with the prespeci-
fied stratification of high (avgSUVmax >4) versus low
(avgSUVmax ≤4) uptake (Table 3). The average change in
tumor size in the high- and low-uptake groups was
0.57% (range from 32.7% to 35.9%) and 1.4% (range
from 31.7% to 17.3%), respectively (P = 0.69; t-test on
the log scale). As a sensitivity analysis, patients were clas-
sified into low- and high-uptake groups based on the
median baseline SUVmax among evaluable patients, but
no differences in tumor size change were found
(P = 0.43). We also evaluated avgSUVmax as a continu-
ous predictor, and the relationship was not statistically
significant. Similarly, no significant differences were seen
for SUVmax.
The relationship between early changes in SUV uptake
and tumor size changes were examined using linear
regression models and log-transformed tumor size
changes. Average SUVmax changes (Fig. 2B) ranged from
75.3% to 0% and showed a modest but statistically sig-
nificant correlation with changes in tumor size
(P = 0.013; R2 = 0.13) (Table 3). This effect was seen in
the clear cell only cohort (n = 35) as well (P = 0.027,
Figure 1. Patient disposition of this clinical trial exploring FDG-PET as
a predictive biomarker for therapy with everolimus in metastatic renal
cell carcinoma.
Table 1. Baseline demographics (evaluable patients, n = 50).
Variable Median (range) or total (%)
Age 60 (36–79)
Sex (female) 15 (30)
Number of lines of previous treatment 2 (1–4)
Tumor type
Clear cell 36 (72)









SUVmax ≤4 (all): 18 (36%)
All 9 (18)




Baseline average SUVmax (all)
All 6.6 (1–17.9)




Average SUVmax ≤4 (all): 20 (40%)
All 10 (20)
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R2 = 0.14). Early changes in SUVmax from baseline to
2 weeks ranged from 74.8% to 76.9% (an increase
occurred in a single patient), and were not significantly
associated with subsequent tumor size change at 8 weeks
(P = 0.12; R2 = 0.05).
We explored the association between baseline avgSUV-
max and OS and PFS, as well. Patients in the high
(avgSUVmax >4) uptake group had worse outcome for
both OS (HR = 3.99, P=0.023) and PFS (HR = 2.85,
P = 0.02). The effect remained significant when we com-
pared groups split at the median uptake value both for OS
(HR = 2.1; P = 0.036) and PFS (HR = 1.91; P = 0.046).
Although a trend toward significance was noted for OS,
this effect disappeared when we examined only the clear
cell subtype (HR = 3.0; P = 0.14) (Fig. 3).
We then examined the effect of the early relative
changes in avgSUVmax. None of the patients had a dis-
ease progression or death prior to the second FDG-PET
scan, and therefore all patients were included in this anal-
ysis. Early changes were not significantly associated with
PFS or OS (HR = 1.00 and 0.99, respectively) overall or
among the clear cell subtype. Regarding the association of
PFS or OS with RECIST-based response, given the low
RECIST response rate, there was no correlation between
this metric and any FDG uptake metric, either.
Discussion
This clinical trial evaluated the role of FDG-PET as a bio-
marker of clinical impact from everolimus therapy in
patients with metastatic RCC. Although our initial
hypothesis centered on baseline SUVmax as a predictor
for change in tumor size, no relationship between these
parameters was detectable. Instead, we observed a signifi-
cant association between baseline SUVmax and OS and
PFS. Such a conclusion would need to be confirmed in a
larger clear cell cohort. As everolimus does not commonly
Table 2. Response to treatment (RECIST-based tumor size changes at
2 months).
Subtype
Percent change in tumor size
(mean, range) and RECIST response
category (n, %)
All subtypes (n = 50) 0.18% (32.7% to +35.9%)
Progression of disease 5 (10%)
Stable disease 43 (86%)
Partial response 2 (4%)
Complete response 0 (0%)
Clear cell (n = 36) 2.0% (32.7% to +35.9%)
Progression of disease 3 (8.3%)
Stable disease 31 (86.1%)
Partial response 2 (5.6%)
Complete response 0
Papillary (n = 4) 1.4% (14.5% to +16.0%)
Stable disease 4 (100%)
Chromophobe (n = 4) 1.1% (5.0% to +3.0%)
Stable disease 4 (100%)
Unclassified (n = 6) 11.7% (15.1% to +35.9%)
Progression of disease 2 (33.3%)
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Figure 2. (A) RECIST-based changes in tumor size at 8 weeks post treatment with everolimus are heterogeneous as seen in the waterfall plot.
(B) FDG-PET uptake decreased after 2 weeks of treatment for most renal cancer patients.
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result in dramatic tumor size changes, future trials may
need to consider using a PFS or OS endpoint.
As previously noted, we documented consistent differ-
ences in baseline SUVmax among different RCC sub-
types. These differences point to marked differences in
biology and metabolic programming among renal cell
subgroups. Although the numbers of individual tumor
types were small for all but the clear cell subgroup, we
observed a trend toward increased glucose uptake, consis-
tent with previously suggested increased activation of the
mTOR pathway among papillary type RCCs [21]. As
noted prior by Ho et al. [22], the chromophobe subtype
of RCC was noted to have relatively low glucose uptake.
Interestingly, patients with higher avgSUVmax had worse
outcome for both overall and PFS. This post hoc analysis
not only speaks of the heterogeneity among histologic
subtypes but also reaffirms that FDG-PET has the poten-
tial to be an early noninvasive prognostic measure of
outcome [22].
As expected, we did demonstrate a pharmacodynamic
effect of everolimus on FDG-PET uptake. However, there
was only a modest correlation between changes in glucose
uptake and tumor size metrics and no relationship with
PFS or OS. This finding recapitulates those published by
Kayani et al. They examined clear cell renal cell patients
undergoing VEGFR tyrosine kinase inhibition. In their
analysis, FDG-PET/CT changes became significantly corre-
lated with RECIST response at 16 weeks follow-up [11]
rather than at an earlier 8-week timepoint. Indeed, 86% of
patients had stable disease at the first interval imaging
point. Therefore, it is possible that if we had repeated a
FDG-PET evaluation at a later timepoint, we may have
seen a stronger relationship with response to treatment.
Nevertheless, this may obviate the clinical predictive value
of this expensive biomarker. For example, if we were to use
a 16-week endpoint, 13 (26%) of the fifty 8-week evaluable
patients in this study who had not come off the trial for
drug toxicity would have already reached progression crite-
ria or died before the second FDG-PET evaluation.
Additionally, our clinical findings are also similar to
those reported by Ma et al. [23] in which 34 patients
with various solid malignancies treated with the related
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Figure 3. Kaplan–Meier estimates of overall survival among patients with high (>4) and low (≤4) baseline avgSUVmax. (A) Significant difference
in overall survival among all patients (n = 50). (B) The overall survival difference is no longer statistically significant among the clear cell subtype
(n = 36).







Baseline SUVmax (≤4 vs >4)1 NS NS
Baseline SUVmax (continuous)2 NS NS
Baseline avgSUVmax (continuous)2 NS NS
Δ%SUVmax (continuous) NS NS
Δ%avgSUVmax (continuous) P = 0.01 P = 0.03
SUVmax, maximum standardized uptake value (SUVmax) of the most
FDG avid lesion; aveSUVmax, the average SUVmax of all measured
lesions; Δ%SUVmax, percent change from SUVmax at baseline to
2 week reevaluation; Δ%aveSUVmax, change from aveSUVmax at
baseline to 2 week reevaluation; NS, not significant.
1t-test.
2Linear regression, log-transformed measure.
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uptake. As in our trial, however, change in FDG uptake
was not predictive of time to progression [24]. Taken
together, changes in FDG values therefore may not be as
relevant as baseline values.
Although we were unable to provide support for the
value of FDG-PET as a clinically useful biomarker in the
context of mTOR inhibition in renal cancer, a number of
limitations should be recognized. The number of fully
evaluable patients was less than originally planned and
thus the study’s power for detecting an effect is modest
and extrapolation to survival impact should be performed
cautiously. In addition, the study enrolled a hetero-
geneous group of patients and was not powered to detect
the hypothesized effect in the clear cell subgroup. In addi-
tion, we were unsuccessful at retrieving six unclassified
historical pathologic specimens for further review, and
this introduces the potential for inaccuracies in histologic
subtyping.
Given these caveats, FDG-PET metrics are only mod-
estly correlated with clinical impact of everolimus on sur-
vival endpoints and tumor burden in metastatic RCC, a
large effect size is unlikely, and additional studies of this
expensive biomarker in renal cancer for this purpose are
not recommended. We did observe consistent differences
in baseline SUVmax between histologic subtypes, which
undoubtedly underlie their unique biological properties.
Thus, an important relationship between tumoral FDG
avidity and outcome to targeted therapy may exist.
Should any future studies of FDG-PET in renal cancer be
performed, a histologically uniform group of tumors
must be taken into consideration.
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